Followers | 2529 |
Posts | 69942 |
Boards Moderated | 1 |
Alias Born | 07/30/2012 |
Monday, April 08, 2019 5:11:19 PM
739% Increase in revenue for the 4th quarter of 2018 at $35.5 million, year over year
Total revenue for the year is $96.4 million
52-wk high was $46.00 52-week low was $3.22
Insider and Institutional Ownership at 60%
https://marketwirenews.com/news-releases/melinta-therapeutics-announces-multiple-presentations-at-the-29th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid--7962006.html
MORRISTOWN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that researchers are scheduled to present multiple scientific data presentations with data from its antibiotic portfolio at this year’s 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 13-16 in Amsterdam, Netherlands.
“The body of data presented at ECCMID represents an important step in the global fight against antimicrobial resistance and delivering anti-infective solutions to patients,” said Sue Cammarata, M.D., chief medical officer of Melinta. “We are pleased that these data will be shared within the infectious disease community to further elucidate the value and utility of these anti-infective agents.”
Key data presentations at ECCMID 2019 include:
Integrated Symposium Presentations
•“Update on acute bacterial skin and skin structure infection: current challenges and new therapeutic agents,” chaired by Javier Garau, M.D., Ph.D. (Saturday, April 13, 1:30 - 3:30 p.m., Hall D)
•“Light and shadows in the management of serious MDR G-negative infections,” chaired by Matteo Bassetti, M.D. (Monday, April 15, 4:00 p.m. – 6:00 p.m., Hall F)
Oral Presentation
•Abstract No. 3623 (Sunday, April 14, 11:00 a.m. - 12:00 p.m. CET, Exhibit Hall L): Development and Validation of a Risk Stratification Score for a Mixed Gram-Negative and Gram-Positive Infections among Patients Hospitalized with Skin and Skin Structure Infections in the U.S., Y. Tabek, BD.
Poster Presentations
Meropenem/vaborbactam (VABOMERE®)
•Abstract No. 8308 (Saturday, April 13, 3:30 - 4:30 p.m. CET, Paper Poster Area): Activity of meropenem-vaborbactam and single-agent comparators against KPC-producing Enterobacterales isolates from European countries (2016-2018) stratified by infection type, M. Castanheira, JMI Laboratories
•Abstract No. 2825 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram-Negative MIC Panels, A. Harrington, Loyola University
•Abstract No. 4780 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): ETEST meropenem/vaborbactam for antimicrobial susceptibility testing of Enterobacterales and Pseudomonas aeruginosa: performance results from a multi-centre study, C. Anglade, bioMérieux, Inc.
•Abstract No. 7426 (Tuesday, April 16, 12:30 - 1:30 p.m. CET, Paper Poster Area): An FDA-approved study for an AST disc 510(k) submission: comparison of an oxoid AST disc to a predicate AST disc for meropenem-vaborbactam, N. Hunter, Thermo Fisher Scientific
Delafloxacin (BAXDELA®)
•Abstract No. 6363 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Delafloxacin tentative ECOFF values for common Gram-positive and Gram-negative bacteria, G. Menchinelli, Università Cattolica del Sacro Cuore
Oritavancin (ORBACTIV®)
•Abstract No. 4151 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018), C. Carvalhaes, JMI Laboratories
Total revenue for the year is $96.4 million
52-wk high was $46.00 52-week low was $3.22
Insider and Institutional Ownership at 60%
https://marketwirenews.com/news-releases/melinta-therapeutics-announces-multiple-presentations-at-the-29th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid--7962006.html
MORRISTOWN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that researchers are scheduled to present multiple scientific data presentations with data from its antibiotic portfolio at this year’s 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 13-16 in Amsterdam, Netherlands.
“The body of data presented at ECCMID represents an important step in the global fight against antimicrobial resistance and delivering anti-infective solutions to patients,” said Sue Cammarata, M.D., chief medical officer of Melinta. “We are pleased that these data will be shared within the infectious disease community to further elucidate the value and utility of these anti-infective agents.”
Key data presentations at ECCMID 2019 include:
Integrated Symposium Presentations
•“Update on acute bacterial skin and skin structure infection: current challenges and new therapeutic agents,” chaired by Javier Garau, M.D., Ph.D. (Saturday, April 13, 1:30 - 3:30 p.m., Hall D)
•“Light and shadows in the management of serious MDR G-negative infections,” chaired by Matteo Bassetti, M.D. (Monday, April 15, 4:00 p.m. – 6:00 p.m., Hall F)
Oral Presentation
•Abstract No. 3623 (Sunday, April 14, 11:00 a.m. - 12:00 p.m. CET, Exhibit Hall L): Development and Validation of a Risk Stratification Score for a Mixed Gram-Negative and Gram-Positive Infections among Patients Hospitalized with Skin and Skin Structure Infections in the U.S., Y. Tabek, BD.
Poster Presentations
Meropenem/vaborbactam (VABOMERE®)
•Abstract No. 8308 (Saturday, April 13, 3:30 - 4:30 p.m. CET, Paper Poster Area): Activity of meropenem-vaborbactam and single-agent comparators against KPC-producing Enterobacterales isolates from European countries (2016-2018) stratified by infection type, M. Castanheira, JMI Laboratories
•Abstract No. 2825 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram-Negative MIC Panels, A. Harrington, Loyola University
•Abstract No. 4780 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): ETEST meropenem/vaborbactam for antimicrobial susceptibility testing of Enterobacterales and Pseudomonas aeruginosa: performance results from a multi-centre study, C. Anglade, bioMérieux, Inc.
•Abstract No. 7426 (Tuesday, April 16, 12:30 - 1:30 p.m. CET, Paper Poster Area): An FDA-approved study for an AST disc 510(k) submission: comparison of an oxoid AST disc to a predicate AST disc for meropenem-vaborbactam, N. Hunter, Thermo Fisher Scientific
Delafloxacin (BAXDELA®)
•Abstract No. 6363 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Delafloxacin tentative ECOFF values for common Gram-positive and Gram-negative bacteria, G. Menchinelli, Università Cattolica del Sacro Cuore
Oritavancin (ORBACTIV®)
•Abstract No. 4151 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018), C. Carvalhaes, JMI Laboratories
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.